Xilis’ proprietary #MicroOrganoSphere™ (MOS) technology represents a new standard in patient-derived micro-tumor production. From each patient, MOS retains unique patient tissue structure, genetic alterations, gene expression, immune microenvironment and histopathology. Overcoming major limitations of widely used, yet limited, models including xenografts and #organoids, MOS offers unprecedented speed, scalability, and predictivity in a small-scale model, opening up tremendous opportunities using patient-derived micro-tumors in drug development and discovery as well as drug prioritization assays for patients.
xilis
Biotechnology
Durham, North Carolina 6,062 followers
Next generation technologies for precision medicine.
About us
Developing next generation technologies for precision medicine and drug discovery.
- Website
-
http://www.xilis.net
External link for xilis
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Durham, North Carolina
- Type
- Privately Held
- Founded
- 2019
- Specialties
- organoids, precision medicine, oncology, cancer, tissue engineering, microfluidics, Artificial Intelligence, and precisiononcology
Locations
-
Primary
Get directions
801 Capitola Dr
Suite 12
Durham, North Carolina 27713, US
-
Get directions
400 Oyster Point Boulevard
Suite 539
South San Francisco, California 94080, US
Employees at xilis
-
Hans Smith
Executive Director, Legal & Head of Intellectual Property at Xilis
-
Charlie Cooper
Laboratory automation and high-throughput specialist with a background in biochemical engineering and experience in regulated environments
-
Alaa Halawa
Investing in and building transformative companies at the intersection of technology and healthcare
-
Wesley Chan
Co-Founder & Managing Partner of FPV Ventures. Canva Series A Lead and Board Member. Forbes Midas List investor.
Updates
-
We are very proud and excited to announce that Xilis is listed as one of the most promising startups of 2023 by Business Insider! https://lnkd.in/dKZTyxcV